Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1600 1644 1649 1674 1675 3783 3792
This examiner grants 54% of resolved cases
Olga N. Chernyshev is an examiner in Tech Center 3700 and Art Unit 1600. The examiner has 960 resolved cases. The data shows an allowance rate of 54.5 percent for these cases. This 54.5 percent rate provides a baseline for applicants to evaluate the probability of success when their applications are assigned to this examiner.
The interview lift for this examiner is 34.4 percent. This 34.4 percent lift is a comparison to the 54.5 percent allowance rate, indicating that direct communication is a factor in the prosecution process. Practitioners can use this figure to evaluate the impact of conducting an interview, as it correlates with an increased probability of reaching an allowance compared to the baseline.
The median days to allowance for Chernyshev is 1087. This 1087-day measure provides an expectation for the duration of the patent prosecution cycle. With 960 resolved cases, the examiner has a history that supports these metrics. The combination of the allowance rate and the 1087-day median pendency helps in planning patent strategies for Art Unit 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18147360 | METHODS OF DIAGNOSING BRAIN INJURY | Final Rejection | Abbott Laboratories |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | Final Rejection | H. Lundbeck A/S |
| 18688256 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROSIS AND SCARRING | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17914121 | COMPOSITIONS AND METHODS FOR TREATING A NEURODEGENERATIVE OR DEVELOPMENTAL DISORDER | Final Rejection | The Regents of the University of California |
| 18027589 | METHODS, COMPOSITIONS, AND KITS FOR DETECTING AND MEASURING ENDOTHELIAL INJURY IN NORMAL AND DISEASED HUMAN CENTRAL NERVOUS SYSTEM (CNS) | Non-Final OA | Ohio State Innovation Foundation |
| 17476078 | Use of LEPR Agonists for Pain | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18657340 | CITRULLINATED BRAIN AND NEUROLOGICAL PROTEINS AS BIOMARKERS OF BRAIN INJURY OR NEURODEGENERATION | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 16489506 | A NOVEL NERVOUS SYSTEM-SPECIFIC TRANSMEMBRANE PROTEASOME COMPLEX THAT MODULATES NEURONAL SIGNALING THROUGH EXTRACELLULAR SIGNALING VIA BRAIN ACTIVITY PEPTIDES | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 16794379 | METHOD FOR INDEXING COGNITIVE FUNCTION | Final Rejection | SHIMADZU CORPORATION |
| 18579800 | A Beta Biomarker of Alzheimer’s Disease Model Mouse and Analysis Method Thereof | Non-Final OA | The University of Tokyo |
| 18028932 | PEPTIDE FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18700972 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 16484953 | Methods and Compositions for Treating Neurodegeneration and Fibrosis | Final Rejection | Temple University-Of The Commonwealth System of Higher Education |
| 17731115 | Treatment of Mood and Anxiety Disorders | Final Rejection | Icahn School of Medicine At Mount Sinai |
| 18557480 | METHODS FOR TREATING VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND RELATED DISORDERS | Non-Final OA | MEDIMMUNE LIMITED |
| 18454598 | COMPOSITIONS, SYSTEMS, AND METHODS FOR DETERMINATION OF T2R AND/OR T1R PHENOTYPE IN INDIVIDUALS TO PREDICT CANNABIS TASTING PREFERENCES, CHARACTERIZATION OF CANNABIS IN RELATION TO INDIVIDUAL TASTING PREFERENCES, AND SELECTION OF CANNABIS | Non-Final OA | Phenomune, LLC |
| 18029239 | COMPOSITION INCLUDING PLGF FOR PREVENTION OR TREATMENT OF NEUROPSYCHOLOGIC DISEASE | Non-Final OA | CEFO CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy